The past 6 months has seen some solid progress and hopefully we get some further news flow/ announcements start coming through.
Period
Milestone
1
Oct-21
MRSA Analysis Module - (FDA Approval)
2
Oct-21
US Distribution Agreement (Thermo Fisher)
3
Jan-22
CCS Acquisition (JV partners 50%)
4
Mar-22
Purchase Order: 5 x APAS (Thermo Fisher)
The Quarterly should be released next week, whilst ECCMID is also next week (23-26 April).
ECCMID 2022 5 x presentations (poster further below). Good to see new sites/ locations have had the APAS and will be presenting:
University of California San Diego (US);
Bio Med21 (France); and
William Harvey Hospital (UK) who are part of the NHS system.
Pleased they've got the APAS into another NHS site (following the sale to HSL/ Sonic Healthcare). Need to continue penetrating into the NHS network of sites in the UK.
Pipeline Should have some things in the pipeline, and will be looking for update on:
Urine Module (CE Marking - EU regulatory approval)
VRE Module (CE Marking - EU regulatory approval)
AMR (AST) Module (further development and results) - noting Dr Wisplinghoff will be presenting @ ECCMID
Early Plate Reading (further development and data on reducing plate read time <12 hours)
Territory Expansion: Additional territory for distribution (Annual report pg.8)
Industry Expansion: Any further update on product expansion into non-clinical applications (i.e. Water, Dairy, Enviro monitoring)
Further Sales Progress: Thermo have started well with 5x units, whilst Beckman Coulter placed a number of trials in France, UK, Germany late 2021.
Will take it that the share price may have to some extend been caught up with the general tech sector decline over the past 6+ months, but otherwise progress has been made, and the company is in better position - and so hopefully we soon see that reflected in the SP.
